Video

Donna Berry on the Future of Oncology Nursing

Author(s):

Donna L. Berry, PhD, RN

Donna Berry from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the Future of Oncology Nursing

Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute describes her thoughts on the future of oncology nursing; specifically eliminating the science and practice gap.

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Related Content
FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
November 18th 2021

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.
September 28th 2024

The OncFive: Top Oncology Articles for the Week 9/22

Gordan on Growing the Infrastructure for In-House Genomic Testing
October 14th 2021

Gordan on Growing the Infrastructure for In-House Genomic Testing

FDA
September 25th 2024

FDA Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

The FDA has granted fast track designation to EO-3021 for use in select patients with claudin 18.2–expressing gastric or GEJ cancer.
September 24th 2024

FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer